← Back to Clinical Trials
Recruiting NCT06595784

NCT06595784 The HELlenic Thoracic Society Initiative for CΟPD and CVD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06595784
Status Recruiting
Phase
Sponsor Hellenic Thoracic Society
Condition Chronic Obstructive Pulmonary Disease (COPD)
Study Type OBSERVATIONAL
Enrollment 900 participants
Start Date 2024-10-15
Primary Completion 2026-10

Trial Parameters

Condition Chronic Obstructive Pulmonary Disease (COPD)
Sponsor Hellenic Thoracic Society
Study Type OBSERVATIONAL
Phase N/A
Enrollment 900
Sex ALL
Min Age 35 Years
Max Age 99 Years
Start Date 2024-10-15
Completion 2026-10

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.

Eligibility Criteria

Inclusion criteria Patients should cumulatively meet the following three (3) criteria to be enrolled in the study: 1. To have been diagnosed with chronic obstructive pulmonary disease and at least one cardiovascular comorbidity (heart failure, atherosclerotic cardiovascular disease, atrial Fibrillation, severe valvular disease) 2. Adults aged \>35 years at the time of inclusion in the study, 3. With signed informed consent for their participation in the study. Exclusion criteria Patients with the below limitations are not eligible to participate in the study Patients: 1. Without at least one cardiovascular comorbidity, 2. With history of lung cancer 3. With any other active malignancy and undergoing treatment (chemotherapy/radiotherapy/immunotherapy) 4. With any thoracic or abdominal surgery planned during study follow-up period 5. With participation in any COPD-related interventional study at study entry or during study duration. 6. Without signed informed consent for their partici

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology